“We also discovered that participants treated with orlistat experienced twice as many days with adverse events as participants treated with placebo… Furthermore, compared with the placebo group, adverse events in the orlistat group were more severe... [however] None of this was stated in the [clinical study reports] or in the published paper,” according to an analysis of orlistat studies by Prof. Peter Gotzsche, MD and others from the Cochrane Collaboration.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.